yahoo_financeOriginal article
Update: UniQure Says Additional AMT-130 Data Show Weaker Results at 4 Years; Shares Tumble
Data ReadoutnegativeAMT-130Negative
AI Analysis
Summary
UniQure announced additional data for AMT-130 showing weaker efficacy results at the 4-year timepoint, causing share price decline.
Clinical Trial Data
Primary Endpoint
Not Met
Outcome Details
Additional AMT-130 data show weaker results at 4 years
Importance:7/10
Sentiment:
-0.80
clinical_datanegative_resultsshare_decline
Related Companies
Read the original article
Published by yahoo_finance on September 29, 2026 6:46 PM